Biopharmaceuticals - Regenerative Medicine / Wound Care
Strategic Profile
The company leverages proprietary enzymatic technology to offer safer, more effective alternatives to surgical debridement. With a cGMP-certified manufacturing facility and strategic partnerships including Vericel Corp for U.S. distribution, MediWound has treated over 16,000 patients globally and is positioned as a leader in advanced wound care innovation.
Cyborg Score Rationale
MediWound has strong commercial validation with FDA-approved NexoBrid generating meaningful revenue, a robust Phase III pipeline asset in EscharEx targeting a large market, and significant manufacturing capacity expansion underway. However, recent quarterly revenues have declined year-over-year and the stock has underperformed, creating execution risk.
Top Insights
NexoBrid achieved FDA approval and orphan drug designation, with active commercialization generating approximately $20.9M trailing twelve-month revenue as of September 2025
EscharEx Phase III VALUE trial progressing for chronic wounds, with clinical data showing superiority over existing $370M+ market standard of care
Manufacturing facility expansion commissioned and approaching full operational capacity by end of 2025, enabling significant scale-up of NexoBrid production
Stock trading at $17.28 (Feb 27, 2026) represents recovery from lows but remains below historical highs, reflecting market skepticism on near-term commercialization trajectory
Named Competitors
SANTYL (collagenase) — FDA-approved collagenase for wound debridement; current standard of care
Novacor Therapeutics - Chronic Wound Portfolio — Alternative approaches to wound management
Surgical debridement — Surgical intervention for burn and wound care
Recent Developments
(November 2025) Completed commissioning of expanded NexoBrid manufacturing facility with full capacity expected by year-end 2025
(September 2025) NexoBrid highlighted in 36 presentations at European Burns Association Congress; continued enrollment in VALUE Phase III trial
(May 2025) Q1 2025 revenue of $4.0M reported; EscharEx development advancing with continued research collaborations
Open the full interactive MediWound Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.